Hazlett, Burt & Watson’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
Hazlett, Burt & Watson's NVO Position: Q3 2026 in Review
Hazlett, Burt & Watson reduced its Novo Nordisk (NVO) stake by 0.93% in Q3 2026, selling an estimated $3.37K and leaving 7,816 shares worth $297K. The position accounts for 0.08% of the portfolio, ranked #212.
Hazlett, Burt & Watson first reported a position in NVO in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.39M in Q2 2024. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Hazlett, Burt & Watson held 7,816 shares of Novo Nordisk worth $297K as of Q3 2026.
- Hazlett, Burt & Watson sold 73 Novo Nordisk shares in Q3 2026, an estimated $3.37K.
- Novo Nordisk made up 0.08% of Hazlett, Burt & Watson's portfolio in Q3 2026, its #212 holding.
- Hazlett, Burt & Watson first reported a position in Novo Nordisk in Q1 2022 and has held it in 19 quarters since.
- Hazlett, Burt & Watson's Novo Nordisk position peaked at $1.39M in Q2 2024.
- 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Hazlett, Burt & Watson's 13F filing for Q3 2026, filed 4 Nov 2026.